{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045661","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.635905+00:00","generated_at":"2026-06-07T09:04:41.070881+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Matinas BioPharma receives FDA feedback on Phase 3 protocol for MAT2203; meeting set for early Q1 2024","bullets":["FDA provided written comments on revised Phase 3 protocol for MAT2203 in invasive aspergillosis with limited treatment options.","Company invited to meeting early Q1 2024 to finalize Phase 3 study design.","Partnership discussions for MAT2203 remain ongoing.","Goal is single Phase 3 registration trial for approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045661","json":"https://secwatch.observer/filing/0001493152-23-045661.json","markdown":"https://secwatch.observer/filing/0001493152-23-045661.md","text":"https://secwatch.observer/filing/0001493152-23-045661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045661/0001493152-23-045661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045661/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:04:41.070881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}